Eculizumab

Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies^[1][2]. IC50 & Target:Complement C5 In Vitro: Eculizumab (3-100 μg/mL) completely prevents MAC deposition, terminal axonal neurofilament loss, and damage to perisynaptic Schwann cells, and inhibits the increase in MEPP frequency, asynchronous twitching of muscle fibres, and the occurrence of 'silent' NMJs, and prevents CGM3/NHS-induced loss of contraction force in a concentration-dependent manner in the in vitro MFS model^[1].
In Vivo: Eculizumab (200 μg; i.v.; before intraperitoneal injection of NHS) completely prevents the development of weakness, respiratory difficulties, and almost completely prevents the occurrence of 'silent' NMJs, and preserves the normal contraction and NMJ function in the in vivo Miller Fisher syndrome (MFS) mouse model^[1].